Latest Headlines

Latest Headlines

Dynavax shares spike on promising Heplisav data

Shares of Dynavax Technologies soared 35 percent after the developer announced that its hepatitis B vaccine Heplisav produced promising data in a mid-stage study, protecting patients with chronic

Dynavax gets green light to resume hep B vax program

The FDA is giving Dynavax Technologies a green light to resume testing of a late-stage hepatitis B vaccine that had been derailed 18 months ago after a patient in one study developed a rare

Dynavax explores new strategy for Heplisav

Dynavax Technologies has been talking with regulators in Europe about the potential for developing Heplisav, an experimental hepatitis B vaccine, for people over 40 who aren't responding to currently

Dynavax tanks on feds' Heplisav stance

Shares of Dynavax Technologies plunged 75 percent after company officials announced that U.S. regulators were asking for more information on its hepatitis B Vaccine and was

Merck, Dynavax announce Heplisav results

Dynavax and Merck announced that their hepatitis B vaccine Heplisav achieved the primary endpoint in a Phase III study. In the study, 95.1 percent of subjects who received Heplisav developed

Dynavax inks universal vaccine pact with Novartis

Dynavax Technologies and Novartis Vaccines and Diagnostics are teaming up on an effort to develop a new universal flu vaccine. Novartis Vaccines, which includes the old Chiron ops it bought out, will